UID:
edoccha_9960073523302883
Format:
1 online resource (365 p.)
Edition:
2nd ed.
Content:
Principles of Translational Science in Medicine: From Bench to Bedside, Second Edition, provides an update on major achievements in the translation of research into medically relevant results and therapeutics. The book presents a thorough discussion of biomarkers, early human trials, and networking models, and includes institutional and industrial support systems. It also covers algorithms that have influenced all major areas of biomedical research in recent years, resulting in an increasing numbers of new chemical/biological entities (NCEs or NBEs) as shown in FDA statistics. The book is ideal for use as a guide for biomedical scientists to establish a systematic approach to translational medicine. Provides an in-depth description of novel tools for the assessment of translatability of trials to balance risk and improve projects at any given stage of product development New chapters deal with translational issues in the fastest growing population (the elderly), case studies, translatability assessment tools, and advances in nanotherapies Details IPR issues of translation, especially for public-private-partnerships Contains contributions from world leaders in translational medicine, including the former NIH director and authorities from various European regulatory institutions.
Note:
Description based upon print version of record.
,
Front Cover; Principles of Translational Science in Medicine; Copyright; Contents; List of Contributors; Preface; Chapter 1 - Introduction and Definitions; WHAT IS TRANSLATIONAL MEDICINE?; PRIMARY TRANSLATION VERSUS SECONDARY TRANSLATION; THE HISTORY OF TRANSLATIONAL MEDICINE, OBSTACLES, AND REMITS; WHAT TRANSLATIONAL MEDICINE CAN AND CANNOT DO; THE PRESENT STATUS OF TRANSLATIONAL MEDICINE (INITIATIVES AND DEFICIENCIES); TRANSLATIONAL SCIENCE IN MEDICINE: THE CURRENT CHALLENGE; REFERENCES; Chapter 2 - Target Identification and Validation
,
Chapter 2.1.1 - "Omics" Translation: A Challenge for Laboratory MedicineINTRODUCTION; "OMICS": WHAT DOES IT MEAN?; PROTEOMICS AS A PARADIGM OF PROBLEMS IN TRANSLATIONAL MEDICINE; DEVELOPMENT OF BIOMARKERS: FROM DISCOVERY TO CLINICAL APPLICATION; DISCOVERY; IDENTIFICATION/CHARACTERIZATION; VALIDATION; STANDARDIZATION/HARMONIZATION; CLINICAL ASSOCIATION AND CLINICAL BENEFIT; TRANSLATING OMICS INTO CLINICAL PRACTICE; CONTINUUM OF TRANSLATION RESEARCH AND OMICS; CONCLUSIONS; REFERENCES; Chapter 2.1.2 - "Omics" Technologies: Promises and Benefits for Molecular Medicine; INTRODUCTION; GENOMICS
,
METABOLOMICSCONCLUSION; REFERENCES; Chapter 2.1.3 - Potency Analysis of Cellular Therapies: The Role of Molecular Assays; POTENCY TESTING; COMPLEXITIES ASSOCIATED WITH POTENCY TESTING OF CELLULAR THERAPIES; FACTORS AFFECTING THE POTENCY OF CELLULAR THERAPIES; MEASURING POTENCY OF CELLULAR THERAPIES; GENE EXPRESSION ARRAYS FOR POTENCY TESTING; POTENTIAL APPLICATIONS OF GENE EXPRESSION PROFILING FOR POTENCY TESTING; MICRORNAS AS POTENCY ASSAYS; CONCLUSIONS; REFERENCES; Chapter 2.1.4 - Translational Pharmacogenetics to Support Pharmacogenetically Driven Clinical Decision Making; INTRODUCTION
,
PHARMACOGENETICS AS A TOOL FOR IMPROVING INDIVIDUAL DRUG THERAPYTYPES OF DRUG THERAPIES THAT MIGHT PROFIT FROM PHARMACOGENETIC DIAGNOSTICS; THE STATUS OF TRANSLATIONAL PHARMACOGENETICS IN VARIOUS DRUG THERAPY FIELDS; TRANSLATIONAL PHARMACOGENETICS AND THE NEED FOR CLINICAL STUDIES TO SUPPORT PHARMACOGENETICALLY DRIVEN PRESCRIBING; REFERENCES; Chapter 2.1.5 - Tissue Biobanks; INTRODUCTION; PRINCIPLES AND TYPES OF TISSUE BIOBANKS: PROS AND CONS; DEVELOPMENTS IN VASCULAR BIOBANKING RESEARCH AND CLINICAL RELEVANCE; CHALLENGES FOR FUTURE BIOBANKS; SUMMARY; REFERENCES
,
Chapter 2.1.6 - Animal Models: Value and Translational PotencyWHAT IS THE VALUE OF ANIMAL MODELS? PATHOPHYSIOLOGICAL CONCEPTS; WHAT IS A GOOD ANIMAL MODEL FOR TRANSLATIONAL RESEARCH?; WHAT IS THE TRANSLATIONAL VALUE OF ANIMAL MODELS?; REMEDIES FOR FAILED TRANSLATION: IMPROVING PRECLINICAL RESEARCH; SUMMARY; REFERENCES; Chapter 2.1.7 - Localization Technologies and Immunoassays: Promises and Benefits for Molecular Medicine; INTRODUCTION; LOCALIZATION TECHNOLOGIES; IMMUNOASSAYS; CASE STUDY: SCREENING OF A BIOMARKER FOR KIDNEY INJURY USING LOCALIZATION AND IMMUNOASSAYS; REFERENCES
,
Chapter 2.1.8 - Biomarkers in the Context of Health Authorities and Consortia
,
English
Additional Edition:
ISBN 0-12-800721-4
Additional Edition:
ISBN 0-12-800687-0
Language:
English
Bookmarklink
